{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T03:33:38Z","timestamp":1779939218847,"version":"3.53.1"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The objective of the study was to construct and validate a predictive model for the clinical efficacy of bronchoalveolar lavage (BAL) with fiberoptic bronchoscopy in patients with community-acquired severe pneumonia based on inflammatory response indicators and blood gas analysis results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A total of 206 patients with severe pneumonia who underwent BAL treatment in our hospital from November 2020 to November 2024 were enrolled and randomly divided into a training set (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f144) and a validation set (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f62) in a 7:3 ratio. In the training set, efficacy-related indicators were screened using univariate analysis. After variable selection via a least absolute shrinkage and selection operator (LASSO) regression analysis, independent factors influencing poor efficacy were determined using multivariate logistic regression analysis. Random forest (RF), K-nearest neighbor algorithm (KNN), and gradient boosting (GB) models were constructed using Python. The performance of the models was evaluated by the area under (AUC) the receiver operating characteristic curve (ROC), and the optimal model was selected.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There were 32 cases (22.22%) and 13 cases (20.97%) with poor clinical efficacy in the training set and the validation set, respectively. In the training set, the multivariate logistic regression analysis showed that age \u2265 60\u202fyears, comorbid chronic obstructive pulmonary disease (COPD), procalcitonin (PCT)\u202f\u2265\u202f2\u202fng\/mL, C-reactive protein (CRP)\u202f\u2265\u202f100\u202fmg\/L, partial pressure of arterial oxygen (PaO\u2082)\u202f&amp;lt;\u202f60\u202fmmHg, and partial pressure of arterial carbon dioxide (PaCO\u2082)\u202f\u2265\u202f50\u202fmmHg were independent risk factors for poor efficacy (all\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.05). The AUC values of the RF model (0.799 in the training set and 0.778 in the validation set) were significantly higher than those of the KNN (0.759, 0.721) and the GB (0.766, 0.738) models, making it the optimal predictive model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>An RF-based predictive model was successfully developed and validated to predict the efficacy of BAL treatment in patients with severe pneumonia. This model effectively identifies and quantifies key factors influencing BAL treatment outcomes in severe pneumonia, providing basic data support for subsequent hypothesis testing and clinical efficacy prediction research. However, as this is a single-center, hypothesis-generating study, the application of the model in individualized treatment planning still requires multicenter external validation and further analysis including a non-BAL control group.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1710355","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T05:14:52Z","timestamp":1767762892000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Machine learning-based prediction model for bronchoalveolar lavage efficacy in severe pneumonia"],"prefix":"10.3389","volume":"12","author":[{"given":"Ning","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s13054-021-03840-x","article-title":"Real-world corticosteroid use in severe pneumonia: a propensity-score-matched study","volume":"25","author":"Ceccato","year":"2021","journal-title":"Crit Care"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.mcna.2024.12.011","article-title":"Severe Pneumonia","volume":"109","author":"Ching","year":"2025","journal-title":"Med Clin North Am"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e065871","DOI":"10.1136\/bmj-2021-065871","article-title":"Management of pneumonia in critically ill patients","volume":"375","author":"Cill\u00f3niz","year":"2021","journal-title":"BMJ"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"779","DOI":"10.23736\/S0026-4806.21.07585-6","article-title":"Pneumomediastinum associated with severe pneumonia related to Covid-19: diagnosis and management","volume":"112","author":"Gandolfo","year":"2021","journal-title":"Minerva Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.cmi.2024.03.008","article-title":"Unexpected increase of severe Mycoplasma pneumoniae pneumonia in adults in southern Switzerland","volume":"30","author":"Garzoni","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1097\/CCM.0000000000005498","article-title":"Etiology, treatments, and outcomes of patients with severe community-acquired pneumonia in a large U.S. sample","volume":"50","author":"Haessler","year":"2022","journal-title":"Crit Care Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1397717","DOI":"10.3389\/fcimb.2024.1397717","article-title":"Microbial signatures predictive of short-term prognosis in severe pneumonia","volume":"14","author":"Huang","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejim.2023.09.007","article-title":"Impact of bronchoalveolar lavage on the management of immunocompromised hosts","volume":"120","author":"Jahn","year":"2024","journal-title":"Eur J Intern Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1266850","DOI":"10.3389\/fimmu.2024.1266850","article-title":"Immune checkpoint inhibitor-related pneumonitis: research advances in prediction and management","volume":"15","author":"Lin","year":"2024","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1136\/thorax-2024-222296","article-title":"Severe community-acquired pneumonia (scap): advances in management and future directions","volume":"80","author":"Martin-Loeches","year":"2025","journal-title":"Thorax"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"107663","DOI":"10.1016\/j.pharmthera.2020.107663","article-title":"Updates on community acquired pneumonia management in the Icu","volume":"217","author":"Nair","year":"2021","journal-title":"Pharmacol Ther"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"125054","DOI":"10.1016\/j.envpol.2024.125054","article-title":"Microplastics, as a risk factor in the development of interstitial lung disease- a preliminary study","volume":"363","author":"\u00d6zgen Alpaydin","year":"2024","journal-title":"Environ Pollut"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"667","DOI":"10.23736\/S0026-4806.22.08467-1","article-title":"Management of pneumonia in the critically ill","volume":"114","author":"Pan","year":"2023","journal-title":"Minerva Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s12931-021-01846-1","article-title":"Oxygenation strategies during flexible bronchoscopy: a review of the literature","volume":"22","author":"Pelaia","year":"2021","journal-title":"Respir Res"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"12157","DOI":"10.3390\/ijms252212157","article-title":"The coexistence of Klebsiella pneumoniae and Candida albicans enhanced biofilm thickness but induced less severe neutrophil responses and less inflammation in pneumonia mice than K. pneumoniae Alone","volume":"25","author":"Phuengmaung","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejim.2025.02.025","article-title":"Comprehensive management of pneumonia in older patients","volume":"135","author":"Putot","year":"2025","journal-title":"Eur J Intern Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1080\/22221751.2022.2035194","article-title":"Aetiology of severe community acquired pneumonia in adults identified by combined detection methods: a multi-Centre prospective study in China","volume":"11","author":"Qu","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.idc.2023.12.005","article-title":"The role of biomarkers in the diagnosis and Management of Pneumonia","volume":"38","author":"Sungurlu","year":"2024","journal-title":"Infect Dis Clin N Am"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1001\/jama.2024.14796","article-title":"Community-acquired pneumonia: a review","volume":"332","author":"Vaughn","year":"2024","journal-title":"JAMA"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1561468","DOI":"10.3389\/fcimb.2025.1561468","article-title":"Clinical application of metagenomic next-generation sequencing in etiologic diagnosis of severe pneumonia in adults","volume":"15","author":"Xing","year":"2025","journal-title":"Front Cell Infect Microbiol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"myae064","DOI":"10.1093\/mmy\/myae064","article-title":"Factors influencing mortality in Covid-19-associated mucormycosis: the international id-Iri study","volume":"62","author":"Sahin","year":"2024","journal-title":"Med Mycol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"139277","DOI":"10.1016\/j.jhazmat.2025.139277","article-title":"Respiratory exposure to 6ppd-quinone aggravates Klebsiella pneumoniae pneumonia by impairing the innate immune function of alveolar macrophages","volume":"496","author":"Qiu","year":"2025","journal-title":"J Hazard Mater"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1710355\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T05:14:54Z","timestamp":1767762894000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1710355\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":22,"alternative-id":["10.3389\/fmed.2025.1710355"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1710355","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"article-number":"1710355"}}